Cargando…
Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers
Cystic fibrosis is a life-threatening disease that affects at least 100,000 people worldwide. It is caused by a defect in the cystic fibrosis transmembrane regulator (CFTR) gene and presently, 360 CFTR-causing mutations have been identified. Since the discovery of the CFTR gene, the expectation of d...
Autores principales: | Cabral, Bernardo, Terlizzi, Vito, Laselva, Onofrio, Conte Filho, Carlos, Mota, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911007/ https://www.ncbi.nlm.nih.gov/pubmed/35268374 http://dx.doi.org/10.3390/jcm11051283 |
Ejemplares similares
-
Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022) -
Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
por: Laselva, Onofrio, et al.
Publicado: (2022) -
Editorial: Mechanisms of Novel Drugs and Gene Modifiers in the Treatment of Cystic Fibrosis
por: Veit, Guido, et al.
Publicado: (2022) -
Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis
por: Silva, Iris A. L., et al.
Publicado: (2022) -
Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
por: Laselva, Onofrio, et al.
Publicado: (2019)